2019 Q4 and annual results
Wednesday, January 29, 2020
|Key figures2||Continuing operations1|
|Net sales||12,403||11,481||8 (cc: 9)|
|Operating income||1,823||1,362||34 (cc: 37)|
|Net income||1,129||1,220||-7 (cc: -6)|
|EPS (USD)||0.50||0.53||-6 (cc: -4)|
|Free cash flow||3,488||2,913||20|
|Operating income||3,462||3,112||11 (cc: 13)|
|Net income||2,985||2,681||11 (cc: 13)|
|EPS (USD)||1.32||1.16||14 (cc: 15)|
- Refers to continuing operations as defined on page 45 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions.
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 58 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.